LUYE PHARMA LTD

Company Registration Number:
11567378 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2024

Period of accounts

Start date: 1 January 2024

End date: 31 December 2024

LUYE PHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 December 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

LUYE PHARMA LTD

Directors' report period ended 31 December 2024

The directors present their report with the financial statements of the company for the period ended 31 December 2024

Principal activities of the company

The principal activities of the Company are trading and sales of pharmaceutical drugs during the year. There were no significant changes in the nature of the Company’s principal activities during the year.



Directors

The directors shown below have held office during the whole of the period from
1 January 2024 to 31 December 2024

JIANG HUA
DELIE BRUNO
ZHANG YEHONG


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
28 August 2025

And signed on behalf of the board by:
Name: DELIE BRUNO
Status: Director

LUYE PHARMA LTD

Profit And Loss Account

for the Period Ended 31 December 2024

2024 2023


£

£
Turnover: 16,131,619 16,237,737
Cost of sales: ( 6,187,511 ) ( 5,894,402 )
Gross profit(or loss): 9,944,108 10,343,335
Distribution costs: ( 783,385 ) ( 778,319 )
Administrative expenses: ( 8,735,969 ) ( 9,159,073 )
Operating profit(or loss): 424,754 405,943
Interest payable and similar charges: ( 340,850 ) ( 174,629 )
Profit(or loss) before tax: 83,904 231,314
Tax: ( 23,954 ) ( 54,359 )
Profit(or loss) for the financial year: 59,950 176,955

LUYE PHARMA LTD

Balance sheet

As at 31 December 2024

Notes 2024 2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 9,203 4,102
Tangible assets: 4 1,197 2,659
Investments: 5 20,036 0
Total fixed assets: 30,436 6,761
Current assets
Stocks: 6 3,203,247 1,379,406
Debtors: 7 8,301,068 7,651,844
Cash at bank and in hand: 1,437,573 1,091,440
Investments:   0 0
Total current assets: 12,941,888 10,122,690
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year: 8 ( 12,415,078 ) ( 9,636,615 )
Net current assets (liabilities): 526,810 486,075
Total assets less current liabilities: 557,246 492,836
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: ( 8,710 ) ( 4,250 )
Accruals and deferred income: 0 0
Total net assets (liabilities): 548,536 488,586
Capital and reserves
Called up share capital: 1 1
Share premium account: 0 0
Other reserves: 0 0
Profit and loss account: 548,535 488,585
Total Shareholders' funds: 548,536 488,586

The notes form part of these financial statements

LUYE PHARMA LTD

Balance sheet statements

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 28 August 2025
and signed on behalf of the board by:

Name: DELIE BRUNO
Status: Director

The notes form part of these financial statements

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

    Turnover policy

    The Company receives revenue for the supply of goods to external customers against orders received. Most contracts that the Company enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical products. Sales of pharmaceutical products are recognized when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. Sales of pharmaceutical products represent net invoice value included fixed and variable consideration. Variable considerations arise on the sales of goods as a result of accrual for estimated future sales rebate. Revenue is not recognized in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The methodology and assumptions used to estimate rebate and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, and projected market conditions. Once the uncertainty associated with rebate is resolved, revenue is adjusted accordingly. Value added tax and other sales taxes are excluded from revenue.

    Tangible fixed assets depreciation policy

    All items of property, plant and equipment are initially recorded at cost. Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Computers Furniture and fittings Office equipment Leasehold improvement - 3 years 3 years 3 to 10 years 3 years The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. The residual value, useful life and depreciation method are reviewed at each financial year-end, and adjusted prospectively, if appropriate. An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on de recognition of the asset is included in profit or loss in the year the asset is derecognised.

    Intangible fixed assets amortisation policy

    The Company leases corporate office space. Rental contracts are typically made for 60 days calculated from the date of lease and thereafter from month to month on a rolling basis. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 4 4

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

3. Intangible assets

Goodwill Other Total
Cost £ £ £
At 1 January 2024 0 4,102 4,102
Additions 0 0 0
Disposals 0 0 0
Revaluations 0 15,339 15,339
Transfers 0 0 0
At 31 December 2024 0 19,441 19,441
Amortisation
At 1 January 2024 0 0 0
Charge for year 0 10,238 10,238
On disposals 0 0 0
Other adjustments 0 0 0
At 31 December 2024 0 10,238 10,238
Net book value
At 31 December 2024 0 9,203 9,203
At 31 December 2023 0 4,102 4,102

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 January 2024 0 0 0 3,854 0 3,854
Additions 0 0 0 0 0 0
Disposals 0 0 0 0 0 0
Revaluations 0 0 0 0 0 0
Transfers 0 0 0 0 0 0
At 31 December 2024 0 0 0 3,854 0 3,854
Depreciation
At 1 January 2024 0 0 0 1,195 0 1,195
Charge for year 0 0 0 1,462 0 1,462
On disposals 0 0 0 0 0 0
Other adjustments 0 0 0 0 0 0
At 31 December 2024 0 0 0 2,657 0 2,657
Net book value
At 31 December 2024 0 0 0 1,197 0 1,197
At 31 December 2023 0 0 0 2,659 0 2,659

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

5. Fixed assets investments note

Investments in subsidiaries are stated at cost less any provision for impairment. In accordance with FRS 101, which applies the recognition and measurement principles of IFRS, directly attributable costs incurred in the acquisition of a subsidiary are included in the cost of investment

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

6. Stocks

2024 2023
£ £
Stocks 3,203,247 1,379,406
Payments on account 0 0
Total 3,203,247 1,379,406

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

7. Debtors

2024 2023
£ £
Trade debtors 5,399,954 5,091,038
Prepayments and accrued income 47,055 2,216,777
Other debtors 2,854,059 344,029
Total 8,301,068 7,651,844
Debtors due after more than one year: 0 0

LUYE PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 December 2024

8. Creditors: amounts falling due within one year note

2024 2023
£ £
Bank loans and overdrafts 0 0
Amounts due under finance leases and hire purchase contracts 0 0
Trade creditors 3,264,633 132,325
Taxation and social security 0 0
Accruals and deferred income 751,284 669,996
Other creditors 8,399,161 8,834,294
Total 12,415,078 9,636,615